ScopiaRx Leadership

Experienced Management Team

Jeffrey Huth, MD, PhD, MPH, Founder

Jeff Huth is the Founder of ScopiaRx, LLC. His work has focused on drug safety at both the molecular and clinical levels for 20 years. Jeff received a BS in Chemistry from Xavier University, a PhD in Pharmacology from the University of Michigan, and an MD degree from the University of Cincinnati College of Medicine. He completed fellowship training in protein biophysics at the National Institutes of Health in the laboratories of Dr. G. Marius Clore and Dr. Angela Gronenborn, and a residency in Occupational Medicine at the University of Cincinnati. Jeff spent 10 years working in the Advanced Technology Division of Pharmaceutical Discovery at Abbott Laboratories. There he invented ALARM NMR, which is a technology to predict adverse drug effects prior to clinical studies. His work in toxicology and fragment based drug design contributed to the development of Viekira, an approved antiviral drug for hepatitis C, and Venclexta, a BCL inhibitor approved for leukemias.  Jeff has authored over 40 publications. He is board certified in Occupational Medicine and currently practices occupational medicine at TriHealth in Cincinnati. In collaboration with investigators at the Department of Environmental Health at the University of Cincinnati College of Medicine, he is exploring the importance of drug safety for patients who have been injured at work.

James J. McGraw Jr, JD, Chairman

Jim McGraw is Chairman of the Board of ScopiaRx, LLC. He is also a Corporate Partner at Keating Muething & Klekamp, and the President and Chief Executive Officer of KMK Consulting Company, LLC. His background is centered in business development, public utilities, insurance and non-profit organizations. His clients include national and international firms in the areas of real estate, financial services, healthcare, energy, manufacturing and technology. He has been actively involved in business and related client consulting for 36 years. Jim focuses on business formation and transactions, acquisitions and divestitures, along with a variety of related strategic work for clients which include corporate growth strategies, organizational design, leadership development, capital formation, public/private partnerships, performance benchmarking and strategic planning. Jim has been involved in numerous life science and healthcare companies, not-for-profits and economic development organizations as General Counsel and as a Board member. Jim has interacted with more than 3,000 CEOs and senior executives in the course of his work and has directed capital initiatives for clients totaling in excess of $500 million.

Allan Wallander, MBA, CFO

Al Wallander came to ScopiaRx in December 2010 with over 15 years of experience in high growth technology companies. He has management experience in financing, accounting, budgeting, board presentations, cash management, investments and strategic planning. Al also provides CFO services to other high growth/high potential organizations including Market6 and DotLoop. He has provided similar services to over 30 other early stage companies since 1997. Previously, Al was with U.S. Shoe Corporation as vice president – finance of footwear retail. Al started his career at Deloitte and earned his BS and MBA from Marquette University.